Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
SFOSF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $10,094,109 | $9,420,323 | $10,155,307 | $10,449,076 |
| % Growth | 7.2% | -7.2% | -2.8% | – |
| Cost of Goods Sold | $5,203,169 | $4,920,296 | $5,475,974 | $5,426,214 |
| Gross Profit | $4,890,940 | $4,500,027 | $4,679,332 | $5,022,862 |
| % Margin | 48.5% | 47.8% | 46.1% | 48.1% |
| R&D Expenses | $979,210 | $737,453 | $996,320 | $786,300 |
| G&A Expenses | -$476,354 | $973,133 | $1,138,694 | $2,629,446 |
| SG&A Expenses | -$55,540 | $3,098,982 | -$3,263,748 | $6,595,948 |
| Sales & Mktg Exp. | $420,814 | $2,125,849 | $2,087,544 | $3,966,502 |
| Other Operating Expenses | $2,564,834 | -$695,179 | $5,809,245 | -$3,537,688 |
| Operating Expenses | $3,488,503 | $3,141,256 | $3,541,817 | $3,844,560 |
| Operating Income | $1,402,437 | $1,358,771 | $1,137,515 | $1,178,302 |
| % Margin | 13.9% | 14.4% | 11.2% | 11.3% |
| Other Income/Exp. Net | -$31,498 | -$11,229 | -$39,799 | -$37,937 |
| Pre-Tax Income | $1,370,940 | $1,347,542 | $1,097,716 | $1,140,365 |
| Tax Expense | $212,295 | $405,976 | $103,793 | $171,579 |
| Net Income | $937,210 | $764,758 | $759,244 | $785,844 |
| % Margin | 9.3% | 8.1% | 7.5% | 7.5% |
| EPS | 0.35 | 0.29 | 0.29 | 0.3 |
| % Growth | 20.7% | 0% | -3.3% | – |
| EPS Diluted | 0.35 | 0.29 | 0.29 | 0.3 |
| Weighted Avg Shares Out | 2,663,353 | 2,663,353 | 2,663,353 | 2,662,659 |
| Weighted Avg Shares Out Dil | 2,663,353 | 2,663,353 | 2,663,353 | 2,662,659 |
| Supplemental Information | – | – | – | – |
| Interest Income | $87,034 | $76,419 | $93,499 | $90,742 |
| Interest Expense | $323,253 | $329,526 | $364,038 | $358,331 |
| Depreciation & Amortization | $0 | $0 | $0 | $320,395 |
| EBITDA | $1,694,193 | $1,677,068 | $1,461,754 | $1,819,091 |
| % Margin | 16.8% | 17.8% | 14.4% | 17.4% |